Meloxicam Apteo Med (Meloxicam)

Meloxicam works by reversibly inhibiting cyclooxygenase enzymes, especially COX‑2. This reduces the synthesis of prostaglandins, which are mediators of inflammation, pain, and fever. By lowering prostaglandin levels, meloxicam diminishes the inflammatory response in affected tissues.

The appropriate dose of meloxicam is determined by the prescribing clinician based on the patient’s condition, severity, age, renal function, and other factors. Typical adult dosing ranges are established in clinical guidelines, but the exact regimen must be individualized and written on the prescription.

The safety of meloxicam in pregnancy and lactation has not been definitively established. It is generally advised to avoid use during the first trimester and to consider alternative therapies. Breastfeeding mothers should discuss potential risks with their healthcare provider before using meloxicam.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Meloxicam offers a longer half‑life than many traditional NSAIDs, allowing once‑daily dosing for many patients. It shows a higher selectivity for COX‑2, which may reduce gastrointestinal irritation compared with non‑selective NSAIDs, though cardiovascular and renal risks remain similar and must be monitored.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from moisture, direct sunlight, and excessive heat. Keep the container tightly closed and out of reach of children.

Meloxicam Apteo Med is taken orally, usually with a full glass of water. It may be taken with or without food, but patients who experience stomach upset are advised to take it with meals. Swallow tablets whole; do not crush or chew them.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as heart attack or stroke, and acute renal failure. Patients should be monitored for signs of severe abdominal pain, sudden swelling, shortness of breath, or changes in urine output, and seek medical attention promptly if they occur.

Meloxicam is contraindicated in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal bleeding or ulcer disease, and patients with severe renal or hepatic impairment. It should also be avoided in patients who have had a recent coronary artery bypass graft surgery.